<DOC>
	<DOCNO>NCT03020264</DOCNO>
	<brief_summary>Diabetes chronic progressive disease affect nearly 3.5 million people France . Currently investigator see age population explain increase life expectancy thus increase incidence diabetes elderly . However , frequency hypoglycemia older vulnerable patient remain poorly characterize</brief_summary>
	<brief_title>Frequency Hypoglycemia Patients With Type 2 Diabetes Under Insulin Therapy Older Than 75 Years Real Life</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<criteria>Male female ≥ 75 year age ; Type 2 diabetes least 1 year treat insulin least 6 month ; Treated basal insulin ( ie glargine U100 : Lantus® , Abasaglar® , glargine U300 : Toujeo® , detemir : levemir® , NPH ) , premix ( ie Novomix® Humalog Mix® ) , / Insulin associate one oral / injectable antidiabetic agent ( analog GLP1 ... ) ; Benefiting least 1 capillary glucose per day ( carried patient caregiver ) ; Benefiting standardize geriatric assessment ; Signature inform consent . Male female age &lt; 75 year ; Person without diabetes type 1 diabetes ; Patient treat lifestyle modification / oral antidiabetic drug / GLP1 receptor agonists alone ; Subjects secondary corticosteroidinduced diabetes ; Refusal participate study inability collect consent ; Patient followup study procedure impossible ( glycemic record impossible insufficient ) ; Patient eligible geriatric assessment ; Patient already participate another study ; Patient severe pathology limit life expectancy ( palliative care ... ) compromise participation study discretion investigator ; Patient benefit safeguard justice .</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Elderly</keyword>
	<keyword>Insulinotherapy</keyword>
</DOC>